• How Viral vIRD Rewires RIPK3 Degradation

  2026-10-05

  Liu et al. identified a conserved orthopoxvirus factor, vIRD, that connects the SCF ubiquitin ligase machinery to RIPK3 degradation and suppression of necroptosis. Their genetic, cellular, and in vivo evidence shows that this interaction can increase viral replication while reshaping inflammation, revealing a direct link between proteasome-dependent immune evasion and poxvirus pathogenesis.

• JHU-083: Glutaminase–Redox Evidence in Models

  2026-10-05

  JHU-083 is examined as a 6-diazo-5-oxo-L-norleucine precursor for interpreting glutaminase and glutamate biology in neurological disease models. This article connects its cerebral CD11b-cell research context with the independent GSTA1–glutathione findings while clearly separating evidence, hypothesis, and applicability.

• Methotrexate: Mechanism, Evidence, and Research Context

  2026-10-04

  Methotrexate is a folate antagonist used to study DHFR inhibition, immune regulation, apoptosis, and cellular persistence. This overview separates supplier-described mechanisms from findings in a 2024 biomimetic chromatography study, explaining what membrane-partitioning data may contribute to methotrexate research—and where pulmonary permeability models cannot support wider clinical or immunological conclusions.

• Epoxomicin and ER Protein Quality Control

  2026-10-03

  How Epoxomicin can help translational researchers interrogate proteasome-dependent protein quality control, ER stress biology, and disease-relevant pathways while keeping mechanistic claims aligned with available evidence.

• EdU Imaging Kits (HF594) for Proliferation

  2026-10-01

  EdU Imaging Kits (HF594) enable direct, fluorescence-based measurement of S-phase DNA synthesis for microscopy and flow cytometry. The workflow is especially useful for testing gefitinib-resistance biology, drug combinations, genotoxic stress, and pharmacodynamic responses while avoiding the DNA denaturation required by BrdU assays.

• ONX-0914 (PR-957) and Hippocampal Plasticity

  2026-10-01

  The reference study shows that chronic inhibition of non-constitutive proteasomes affects tetanus-evoked, but not theta-burst-evoked, hippocampal LTP in mice. Its combination of pathway-selective pharmacology, ex vivo electrophysiology, and hippocampal gene-expression analysis provides a framework for studying how proteasome subtypes contribute to synaptic plasticity.

• Bortezomib (PS-341): Proteasome Research Guide

  2026-09-30

  Bortezomib, also called PS-341, is a reversible 20S proteasome inhibitor used in multiple myeloma research, mantle cell lymphoma research, and apoptosis assays. Its boronic acid pharmacophore enables proteasome inhibition, while cell-line and xenograft data provide model-specific research benchmarks rather than universal potency predictions.

• Troglitazone in PPARγ Agonist TAM Assays

  2026-09-30

  Troglitazone provides a practical PPARγ agonist tool for connecting lipid and glucose metabolism studies with macrophage and renal carcinoma experiments. This guide shows how to use it as a controlled pathway perturbation, distinguish SPP1-related phenotype changes from nonspecific toxicity, and build reproducible translational assays.

• MLN8237 (Alisertib): Assay Workflow Guide

  2026-09-29

  This scenario-driven guide explains how MLN8237 (Alisertib), SKU A4110, can support interpretable Aurora A inhibition, viability, proliferation, and apoptosis experiments. It covers formulation, dose design, orthogonal validation, cross-domain limitations, and practical vendor-selection criteria.

• Sodium Orthovanadate in Insulin Signaling Assays

  2026-09-29

  Sodium Orthovanadate is more than a phosphorylation-preserving reagent: it can separate true cellular signaling from post-lysis signal drift. This guide connects Na3VO4 chemistry with adipocyte insulin-signaling readouts, assay controls, and practical workflow decisions.

• NU6300 Targets GSDMD Cys191 to Block Pyroptosis

  2026-09-28

  The reference study identifies NU6300 as a covalent GSDMD inhibitor that reacts with cysteine-191 and interferes with cleavage, palmitoylation, membrane localization, and oligomerization. Its pathway-dependent effects in inflammasome models, together with activity in colitis and sepsis models, provide a mechanistic framework for developing pyroptosis-directed anti-inflammatory compounds.

• 5-Azacytidine Triggers DNA Damage in Myeloma

  2026-09-28

  A preclinical study found that 5-azacytidine induces ATR-associated DNA damage responses and apoptosis in multiple myeloma cells, including therapy-resistant models. Its reported activity and synergy with doxorubicin or bortezomib support further investigation, while the in vitro evidence does not establish clinical benefit.

• LG 101506: RXR Modulator Workflows in TNBC

  2026-09-27

  Use LG 101506 to test whether RXR modulation changes cellular phenotypes in cancer and metabolism models—not to assume a proven effect on PD-L1. This workflow pairs controlled compound handling with orthogonal RXR, checkpoint, and immune-cell readouts, while separating established TNBC findings from new hypotheses.

• Topotecan HCl: Practical Assay Design

  2026-09-26

  A scenario-driven guide to using Topotecan HCl (SKU B2296) in viability, proliferation, and cytotoxicity workflows. It covers mechanism, concentration and solvent planning, interpretation limits, and practical criteria for selecting a supplier without overstating what the available data establish.

• MLN2238: Mapping Proteasome Stress Signaling

  2026-09-25

  Explore how MLN2238, a potent proteasome β5 subunit inhibitor, can reveal the signaling response to proteotoxic stress. This article connects proteasome perturbation with ROS–JNK–CREB biology while distinguishing established findings from practical assay hypotheses.

8594 records 1/573 page Next 12345 下5页 Last page